Minimum requirements for approval of a drug in status epilepticus.
Baulac
Michel
M
APHP-Neurology Department, La Salpetriere Hospital, University Pierre et Marie Curie, Paris, France. michel.baulac@psl.aphp.fr
Navarro
Vincent
V
D000927:Anticonvulsants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000379:methods; D005060:Europe; D006801:Humans; D010672:Phenytoin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D011355:Prodrugs / Q000009:adverse effects / Q000627:therapeutic use; D012107:Research Design / Q000592:standards; D013226:Status Epilepticus / Q000188:drug therapy*; D016896:Treatment Outcome
D000927:Anticonvulsants; D011355:Prodrugs; D010672:Phenytoin; C043114:fosphenytoin